Saatchi shop rebrands to sharpen specialty focus

Share this article:
Saatchi shop rebrands to sharpen specialty focus
Saatchi shop rebrands to sharpen specialty focus
Saatchi & Saatchi Innovations, Publicis' Pennsylvania-based outpost servicing specialty pharma, is rebranding as Saatchi Science.

The Yardley, PA-based shop is looking to sharpen its brand with the name change.

“It's really a reflection of our “Go Forward” business strategy,” said managing director Annemarie Armstrong. “We're narrowing our focus to broaden our appeal to very specific clients in high science and highly complex categories, like oncology, molecular diagnostics and immunology and vaccines. We wanted an identity that reflects that.”

In addition to the new name, the 65-person shop is investing in analytics capability for oncology. Saatchi Science clients include: Pfizer, for which the firm works on Torisel; AstraZeneca, for Caprelsa and Faslodex; and Sanofi Pasteur, for the vaccines portfolio (both adult and pediatric).

“We're building from our strengths,” said Armstrong. “We believe these are categories, particularly oncology and molecular diagnostics in the era of personalized medicine, are very different than [small molecule therapies], so we're investing in the right mix of marketing strategy, scientific understanding, customer insights and creative communications so that we're focusing all of our resources to deliver for these clients.”

Armstrong was named managing director of the shop in July, having previously served in that role on an interim basis. Previously based in Newton, PA, the agency moved in with Publicis Healthcare Communications Group siblings Publicis Touchpoint Solutions and Publicis HealthWare International last year.

The Saatchi healthcare franchise also includes New York-based Saatchi Wellness, specializing in consumer and patient communications, and Saatchi & Saatchi Health Communications, the network's mainline professional-focused arm. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...